Haijiao Zhang, M.D.

  • Assistant Professor of Division of Oncological Sciences, School of Medicine
  • OHSU Knight Cancer Institute, School of Medicine

Biography

Haijiao Zhang received her Bachelor and Master of Medicine degree from Jilin University in China and then earning an MD at Hannover Medical School in Germany. She joined Dr. Jeffrey Tyner’s laboratory as a postdoc in 2015 .The focus of her research in the Tyner lab has been oncogenic signaling and drug resistance mechanisms associated with hematologic malignancies. Between 2018 and 2019, Dr. Zhang embarked on a year-long visiting scholar opportunity in Dr. Ravi Majeti’s laboratory at Stanford University. In 2021, Dr. Zhang established her laboratory in the Division of Oncological Science at OHSU to study chromosome and copy number aberrations and WT1 in leukemia.

Education and training

  • Degrees

    • B.Med., 2010, Jilin University
    • M.Med., 2012, Jilin University
    • D.Med., 2015, Hannover Medical School

Memberships and associations:

  • American Society of Hematology (ASH)
  • American Association for Cancer Research (AACR)
  • European Hematology Association (EHA)
  • Knight Cancer Institute Translational Oncology Research

Areas of interest

  • Leukemia
  • Wilm’s tumor gene isoforms and mutations
  • Chromosome and Copy Number Deletion
  • Drug biomarkers and resistance mechanism

Publications

Selected publications

  • https://www.ncbi.nlm.nih.gov/myncbi/1X5RFRFTfyjQh/bibliography/public/

Publications

  • Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia

    British Journal of Haematology
    1. Basil Allen
    2. Lindsey Savoy
    3. Peter Ryabinin
    4. Daniel Bottomly
    5. Reid Chen
    6. Bonnie Goff
    7. Anthony Wang
    8. Shannon K. McWeeney
    9. Haijiao Zhang

  • Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

    Signal Transduction and Targeted Therapy
    1. Qi Zhang
    2. Bridget Riley-Gillis
    3. Lina Han
    4. Yanan Jia
    5. Alessia Lodi
    6. Haijiao Zhang
    7. Saravanan Ganesan
    8. Rongqing Pan
    9. Sergej N. Konoplev
    10. Shannon R. Sweeney
    11. Jeremy A. Ryan
    12. Yulia Jitkova
    13. Kenneth Dunner
    14. Shaun E. Grosskurth
    15. Priyanka Vijay
    16. Sujana Ghosh
    17. Charles Lu
    18. Wencai Ma
    19. Stephen Kurtz
    20. Vivian R. Ruvolo
    21. Helen Ma
    22. Connie C. Weng
    23. Cassandra L. Ramage
    24. Natalia Baran
    25. Ce Shi
    26. Tianyu Cai
    27. Richard Eric Davis
    28. Venkata L. Battula
    29. Yingchang Mi
    30. Jing Wang
    31. Courtney D. DiNardo
    32. Michael Andreeff
    33. Jeffery W. Tyner
    34. Aaron Schimmer
    35. Anthony Letai
    36. Rose Ann Padua
    37. Carlos E. Bueso-Ramos
    38. Stefano Tiziani
    39. Joel Leverson
    40. Relja Popovic
    41. Marina Konopleva

  • Gain-of-function mutations in granulocyte colony–stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation

    Journal of Biological Chemistry
    1. Haijiao Zhang
    2. Cody Coblentz
    3. Kevin Watanabe-Smith
    4. Sophie Means
    5. Jasmine Means
    6. Julia E. Maxson
    7. Jeffrey W. Tyner

  • miR-145 contributes to hypertrophic scarring of the skin by inducing myofibroblast activity

    Molecular Medicine
    1. Christiane Gras
    2. Dominica Ratuszny
    3. Catarina Hadamitzky
    4. Haijiao Zhang
    5. Rainer Blasczyk
    6. Constança Figueiredo

  • Allogeneic and xenogeneic anti-tumor effect of Callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction

    Journal of Biological Regulators and Homeostatic Agents
    1. T. Müller
    2. L. Schlahsa
    3. H. J. Zhang
    4. S. Vahlsing
    5. Y. Skaik
    6. B. Eiz-Vesper
    7. S. Immenschuh
    8. R. Blasczyk
    9. Constanca Figueiredo

  • Mir-155 is associated with the leukemogenic potential of the class iv granulocyte colony-stimulating factor receptor in cd34+ progenitor cells

    Molecular Medicine
    1. Haijiao Zhang
    2. Lilia Goudeva
    3. Stephan Immenschuh
    4. Axel Schambach
    5. Julia Skokowa
    6. Britta Eiz-Vesper
    7. Rainer Blasczyk
    8. Constança Figueiredo

  • Semaphorin 3A alters endothelial cell immunogenicity by regulating Class II transactivator activity circuits

    Transfusion
    1. Laura Schlahsa
    2. Haijiao Zhang
    3. Anja Battermann
    4. Murielle Verboom
    5. Stephan Immenschuh
    6. Britta Eiz-Vesper
    7. Renata Stripecke
    8. Katrin Engelmann
    9. Rainer Blasczyk
    10. Constança Figueiredo